Tag: 200-300

On September 6, 2022, Kumar Singh, Adesh; Venkatesh, Rapelly; Kumar Kanaujiya, Vimlesh; Tiwari, Varsha; Kandasamy, Jeyakumar published an article.Electric Literature of 2873-29-2 The title of the article was Palladium-Catalyzed Reaction of Aryl Iodides and Glycal Enones: Application in the Preparation of Dapagliflozin Analogues. And the article contained the following:

An efficient approach for the preparation of C-1 aryl enones from aryl iodides and glycal enones by palladium-catalyzed cross-coupling reactions under ligand-free conditions was developed. A wide range of aryl iodides bearing electron-donating and withdrawing groups underwent oxidative C-1 arylation with galactal, glucal and rhamnal enones in the presence of Pd(OAc)2 and AgNO3 under mild conditions. The protecting groups, including benzyl, acetyl, pivaloyl, and benzoyl groups, were found to be compatible under standard reaction conditions. The developed methodol. was applied for the preparation of dapagliflozin analogs (SGLT-2 inhibitors, no biol. data). Regioselective nitration of C-1 aryl enones provides C-2 nitro aryl enones in good yields. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Electric Literature of 2873-29-2

The Article related to oxidative arylation protecting group sglt2 dapagliflozin, glycoside dapagliflozin analog preparation nitration regioselective cross coupling, palladium catalyzed aryl iodide glycal enone dapagliflozin analog preparation and other aspects.Electric Literature of 2873-29-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 12, 2002, Bryant, Judi A.; Buckman, Brad O.; Islam, Imadul; Mohan, Raju; Morrissey, Michael M.; Wei, Guo Pin; Xu, Wei; Yuang, Shendong published a patent.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of 2-[(piperazinocarbonylmethyl)aminocarbonyl]quinolines as platelet adenosine diphosphate receptor antagonists. And the patent contained the following:

The title compounds [I; a, b = 1-4; A = CH, N; R1 = H, alkyl, aryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = H, alkyl, OH, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, hydroxyalkyl, etc.; R6 = NR7CO, CONR7; R7 = H, alkyl, carboxyalkyl, alkoxycarbonylalkyl], useful as inhibitors of platelet aggregation and thrombus formation, were prepared and formulated. Thus, amidation of 7-methyl-4-hydroxy-2-carboxyquinoline with 4-ethoxycarbonyl-1-[1-amino-3-(1,1-dimethylethoxycarbonyl)propyl]carbonylpiperazine (preparation of both reactants given) afforded 68% I [R1 = CO2Et; R2 = tert-BuOCOCH2CH2; R3 = OH; R4 = 7-Me; R5 = H; R6 = NHCO; A = N]. The compounds I demonstrated their ability to inhibit the binding of [33P]-2-methylthio-ADP binding to the human platelet ADP receptor and the rat platelet ADP receptor. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to piperazinocarbonylmethylaminocarbonyl quinoline preparation platelet adenosine diphosphate receptor antagonist antithrombotic, platelet aggregation inhibitor piperazinocarbonylmethylaminocarbonyl quinoline preparation and other aspects.Safety of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 15, 2019, Wu, Ren-Jun; Ren, Tongtong; Gao, Jie-Yu; Wang, Li; Yu, Qilin; Yao, Zheng; Song, Guo-Qing; Ruan, Wei-Bin; Niu, Cong-Wei; Song, Fu-Hang; Zhang, Li-Xin; Li, Mingchun; Wang, Jian-Guo published an article.Formula: C13H10O3 The title of the article was Chemical preparation, biological evaluation and 3D-QSAR of ethoxysulfuron derivatives as novel antifungal agents targeting acetohydroxyacid synthase. And the article contained the following:

A novel synthesis of 68 ethoxysulfulron (ES) derivatives I [R1 = 2-NO2, 2-COOMe, 2-I(CH2)2O, etc.; R2 = Me, MeO, Cl, Br, I; R3 = Me, MeO] and evaluation of their inhibition constants (Ki) against C. albicans AHAS and cell based min. inhibitory concentration (MIC) values were discussed. The target compounds I [R1 = 2-COOEt; R2 = Me, MeO, Cl, Br, I; R3 = MeO] displayed stronger AHAS inhibitions than ES did. Compound I [R1 = 2-COOEt, R2 = MeO, R3 = MeO] had the best Ki of 6.7 nM against fungal AHAS and MIC values of 2.5 mg/L against Candida albicans and Candida parapsilosis after 72 h. A suitable nematode model was established here and the antifungal activity of compound I [R1 = 2-COOEt, R2 = MeO, R3 = MeO] was further evaluated in-vivo. A possible binding mode was simulated via mol. docking and a comparative field anal. (CoMFA) model was constructed to understand the structure-activity relationship. The current study had indicated that some ES derivatives should be considered as promising hits to develop antifungal drugs with novel biol. target. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Formula: C13H10O3

The Article related to phenyl pyrimidinylcarbamoylsulfamate preparation antifungal acetohydroxyacid synthase inhibition sar docking, acetohydroxyacid synthase, antifungal agents, enzyme inhibition, ethoxysulfuron derivative, nematode model and other aspects.Formula: C13H10O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 31, 2022, Li, Xiang; Liu, Hui; Dun, Matthew D.; Faulkner, Sam; Liu, Xiaoming; Jiang, Chen Chen; Hondermarck, Hubert published an article.Synthetic Route of 2358-84-1 The title of the article was Proteome and secretome analysis of pancreatic cancer cells. And the article contained the following:

Pancreatic cancer is a lethal malignancy and no screening biomarker or targeted therapy is currently available. Here, we performed a shotgun proteomic label-free quantification (LFQ) to define protein changes in the cellular proteome and secretome of four pancreatic cancer cell lines (PANC1, Paca44, Paca2, and BXPC3) vs. normal human pancreatic ductal epithelial cells (HPDE). In the cellular proteome and secretome, 149 and 43 proteins were dysregulated in the most cancer cell lines, resp. Using Ingenuity Pathway Anal. (IPA), the most dysregulated signaling pathways in pancreatic cancer cells included the activation of epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), extracellular regulated kinase (ERK), and the deactivation of type-I interferon (IFN) pathways, which could promote cancer cell progression and decrease antitumor immunity. Parallel reaction monitoring (PRM) mass spectrometry was used to confirm the changes of seven regulated proteins quantified by LFQ: EGFR, growth/differentiation factor 15 (GDF15), protein-glutamine gamma-glutamyltransferase 2 (TGM2), leukemia inhibitory factor (LIF), interferon-induced GTP-binding protein Mx1 (MX1), signal transducer and activator of transcription 1 (STAT1), and serpin B5 (SERPINB5). Together, this proteomic anal. highlights protein changes associated with pancreatic cancer cells that should be further investigated as potential biomarkers or therapeutic targets. The experimental process involved the reaction of Oxybis(ethane-2,1-diyl) bis(2-methylacrylate)(cas: 2358-84-1).Synthetic Route of 2358-84-1

The Article related to pancreatic cancer proteome secretome type i interferon serpinb5 tgm2, lc-ms/ms, prm proteomic, biomarker, label-free quantification, pancreatic cancer, pathway analysis, proteome, secretome, shotgun proteomic, therapeutic targets and other aspects.Synthetic Route of 2358-84-1

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Winterson, Bethan; Rennigholtz, Tim; Wirth, Thomas published an article in 2021, the title of the article was Flow electrochemistry: a safe tool for fluorine chemistry.Recommanded Product: (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate And the article contains the following content:

A scalable, versatile and safe electrochem. fluorination protocol was conferred and strategy proceeded through a transient (difluoroiodo)arene, generated by anodic oxidation of an iodoarene mediator. Even the isolation of iodine(III) difluorides was facile since electrolysis was performed in the absence of other reagents. A broad range of hypervalent iodine mediated reactions afforded 5-(fluoromethyl)-aryl-oxazolines [R = Ph, 2-furanyl, 4-MeOC6H4, etc.], ((2,3-difluoropropoxy)methyl)-aromatic compounds [R1 = Ph, 2-MeC6H4, 4-FC6H4, etc.; R2 = H, Me] and some fluoro compounds R3-F [R3 = 1,3-diphenylpropanyl-1,3-dione, 1-phenyl-1-propanone, 3-phenyldihydrofuran-2(3H)-one, etc.] in high yields by coupling the electrolysis step with downstream reactions in flow, surpassing limitations of batch chem. (Difluoroiodo)arenes were toxic and suffered from chem. instability, so the uninterrupted generation and immediate use in flow was highly advantageous. High flow rates facilitated productivities of up to 834 mg h-1 with vastly reduced reaction times. Integration into a fully automated machine and in-line quenching was key in reducing the hazards surrounding the use of hydrofluoric acid. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Recommanded Product: (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

The Article related to fluoro compound preparation, allyl amide electrochem fluorination hypervalent iodine mediated, alc allyl electrochem fluorination hypervalent iodine mediated, carbonyl compound electrochem fluorination hypervalent iodine mediated and other aspects.Recommanded Product: (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 9, 2012, Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Yamada, Takeshi; Butler, David; Jayaprakash, K. Narayanannair; Jayraman, Muthusamy; Matsuda, Shigeo; Pandey, Rajendra K.; Peng, Chang Geng published a patent.Computed Properties of 53838-27-0 The title of the patent was Preparation of monomers and oligonucleotides comprising triazolyl cycloaddition adducts via click chemical for treating various disorders and diseases. And the patent contained the following:

Oligonucleotides monomers I were prepared and incorporated into RNA, wherein X is O, S, NRN, CRP2; B is independently H, nucleobase, triazole; NH-C(O)-O-C(CH2B1)3, NH-C(O)-NH-C(CH2B1)3; where B1 is halogen, mesylate, N3, CN, triazole, tetrazole; R1-R5 are each independently H, OR6, F, N(RN)2, N3, CN, -J-linker-N3, -J-linker-CN, -J-linker-C-R8, -J-linker-cycloalkyne, -J-cycloalkylidene-linker, -J-heterocyclyl-linker; J is independently absent, O, S, NRN, OC(O)NH, NHC(O)O,C(O)NH, NHC(O), NHSO, NHSO2, NHSO2NH, OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)-NH, OC(S)-NH, O-N=CH, OP(N(RN)2)O, or OP(N(RN)2); R6 is independently H, hydroxy protecting group, alkyl, aryl, cycloalkyl, aralkyl, alkenyl, heteroaryl, polyethylene glycol, phosphate, phosphonate, phosphonothioate, phosphorothiolothionate, phosphodiester, phosphoramidite, solid support, nucleoside, oligonucleotide; RN is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aralkyl, heteroaryl, amino protecting group; RP is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl. Thus, glycoside II was prepared and used in synthesis of DNA duplexes synthesis. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immuno-deficiencies and immunosuppression. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to lipid azide preparation click alkyne rna preparation antiviral human, antiviral parasiticide antitumor immunosuppression autoimmune rna dna duplex preparation, click azide alkyne triazole nucleotide preparation sirna dna peptide and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 6, 2008, Sugita, Kazuyuki; Ohtsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ota, Masahiro; Shibata, Yoshihiro published a patent.Product Details of 141940-37-6 The title of the patent was Preparation of tricyclic heteroaryl compounds as squalene synthetase inhibitors. And the patent contained the following:

There are disclosed 31 specific compounds such as 2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid and (2) 2-(1-[2-[(4R,6S)-8-chloro-6-(2-chloro-3-ethoxyphenyl)-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetyl]-4-piperidinyl)acetic acid which have a squalene synthase inhibition activity and a cholesterol synthesis inhibition activity and are useful as medicinal agents such as prophylactic and/or therapeutic agents for hyperlipemia (including hypercholesterolemia, hypertriglyceridemia and hypo-HDL-cholesterolemia) and/or arteriosclerosis in a mammal including human. Thus, Et [trans-5-(2-bromo-3-methoxyphenyl)-7-chloro-2-thioxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetate was condensed with hydrazine hydrate in THF under ice-cooling for 30 min to give a hydrazone which was cyclocondensed with trifluoroacetic anhydride in dichloroethane first at room temperature for 2 h and then under refluxing for 2 h to give Et [trans-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (I). Chromatog. resolution of I using a Chiralpak AD column and a 2:8 mixture of isopropanol and hexane as the eluent to give Et [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate (II) and Et [(4S,6R)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetate. II was stirred with a 4:1 mixture of AcOH and concentrated H2SO4 at 60° for 7 h to give [(4R,6S)-6-(2-bromo-3-methoxyphenyl)-8-chloro-1-(trifluoromethyl)-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzoxazepin-4-yl]acetic acid (III). III showed IC50 of 0.46 μM against squalene synthase and at 3 mg/kg in vivo inhibited by 98% the synthesis of cholesterol in the liver of rats after 1 h. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Product Details of 141940-37-6

The Article related to cholesterol synthesis inhibitor triazolobenzoxazepinylacetic acid preparation, tricyclic heteroaryl compound preparation squalene synthetase inhibitor, triazolobenzoxazepinylacetic acid preparation squalene synthetase inhibitor and other aspects.Product Details of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 12, 1998, Picard, Joseph Armand; Sliskovic, Drago Robert published a patent.Computed Properties of 53838-27-0 The title of the patent was Preparation of dibenzofuransulfonyl and related amino acids for inhibition of matrix metalloproteinases. And the patent contained the following:

Heterocyclyl sulfonyl amino acids I (R = unnatural amino acid; X = O, S, SO, SO2, CO, NH, alkyl- or alkylphenylimino; R1, R2 = H, alkyl, Ph, NO2, halo, alkoxy, CN, etc.) or their pharmaceutically acceptable salts, esters, amides, and prodrugs were prepared as matrix metalloproteinases inhibitors. Thus, 6-[2-(4-chlorophenoxy)-2-methylpropionylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid, prepared by acylation of 6-amino-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Me ester hydrobromide, showed IC50 >100 μM against MMP-1 and MMP-7. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to amino acid dibenzofuransulfonyl dibenzothiophenesulfonyl preparation activity, dibenzofuransulfonyl amino acid preparation inhibitor metalloproteinase, dibenzothiophenesulfonyl amino acid preparation inhibitor metalloproteinase and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 28, 2013, Koreeda, Tetsuro; Kochi, Takuya; Kakiuchi, Fumitoshi published an article.Formula: C12H14F3NO2 The title of the article was Substituent Effects on Stoichiometric and Catalytic Cleavage of Carbon-Nitrogen Bonds in Aniline Derivatives by Ruthenium-Phosphine Complexes. And the article contained the following:

The reactivity of various o-acylaniline derivatives with Ru complexes was examined The reaction of o-acylanilines with RuH2(CO)(PPh3)3 (1) or an activated Ru species formulated as Ru(CO)(PPh3)3 (4) gave amido hydrido complexes 3 and aryl amido complexes, e.g., I (R = H, Me, OMe, F, CF3), formed via N-H and C-N bond cleavage, resp. Addition of olefins, such as vinylsilanes, accelerates the C-N bond cleavage. The aryl amido complexes I can provide the C-N arylation product upon treatment with arylboronates. The relative reactivity of o-acylanilines bearing various substituents was studied by competition experiments, and electron-donating substituents increase the relative facileness of the C-N bond cleavage in both stoichiometric and catalytic reactions. The trend observed here is different from the one observed for the previously reported Ta-mediated C-N bond cleavage. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Formula: C12H14F3NO2

The Article related to aniline catalytic stoichiometric carbon nitrogen bond cleavage hydridoruthenium phosphine, pivaloylaniline cyclometalation ruthenium hydride complex, ruthenium pivaloylanilido complex preparation catalyst arylation acylaniline and other aspects.Formula: C12H14F3NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 2, 2006, Caroff, Eva; Fretz, Heinz; Hilpert, Kurt; Houille, Olivier; Hubler, Francis; Meyer, Emmanuel published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists. And the patent contained the following:

The invention relates to the preparation of title compounds I [R1 = (un)substituted Ph; W = a bond and R2 = CN, halo/alkoxy/heterocyclyl/cyclo/cycloalkyl/alkyl, hetero/ary/, heterocyclyl, (partially) saturated heterocyclyl; (un)substituted hydroxyalkyl; W = CH2 and R2 = NR7R8, SR9, SO2R10; W = O, S, and R2 = alkoxycarbonyl/carboxy/hydroxy/alkoxy/heterocyclyl/cyclo/ar/heteroaryl/alkyl, hetero/aryl; W = NH and derivatives and R2 = H, dialkylamino/alkoxycarbonyl/hydroxy/alkoxy/cyclo/heterocyclyl/cycloalkyl/ar/diphenyl/heteroaryl/alkyl, aryl, 2-phenylcyclopropyl, COR11, SO2R12, (un)substituted carboxyalkyl; W = CH:CH and R2 = hydroxy/alkoxy/alkyl alkoxycarbonyl, Ph, or CONR13R14; ; or W = CC and R2 = H, hydroxy/alkoxy/alkyl; or W = CO and R2 = alkyl; W = NR3 and NR2R3 = 4-7 membered heterocyclyl; or W = NR3 and NR2R3 = (un)substituted imidazoyl, pyrazolyl, 1,2,3-triazolyl, etc.; R5a, R5b = independently H, Me; R3 = H, alkyl; R7 aryl/alkyl; or NR7R8 = (un)substituted 4-7 membered heterocyclyl; R9 = cycloalkyl, aryl; R10 = cyclo/alkyl, aryl; R11 = alkoxy/alkyl, hetero/aryl, etc.; R12 = alkyl, aryl; R13, R14 = independently alkyl; X = CO and R6 = cyclo/alkyl, alk(ynyl)oxy, aryloxy, aralkoxy, hetero/aryl,aralkyl or NH2 and derivatives; or X = SO2 and R6 = alkyl; Y = a bond and Z = H, aryl substituted by carboxyalkoxy; or Y = alkoxy/Ph/alkoxyphenyl/alkylene, alkoxyphenylene and Z = H, OH, NH2, CO2H, tetrazolyl, CONH2, COOR17, NHCOR17, NHSO2R17; R17 = alkyl], as P2Y12 receptor antagonists. The invention also relates to the use of pyrimidines I and their stereoisomers, salts, solvent complexes and morphol. forms, in the treatment and/or prevention of peripheral vascular, visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases (no data) or conditions associated with platelet aggregation (no data), particularly thrombosis (no data). Thus, a multi-step synthesis starting from Z-L-Glu(Ot-Bu)-OH (Z = benzyloxycarbonyl) and 1-ethoxycarbonylpiperazine was given for amino acid piperazide II. In a P2Y12 binding assay, II had an IC50 = 117 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Category: esters-buliding-blocks

The Article related to amino acid piperazide preparation p2y12 receptor antagonist thrombosis, platelet aggregation pyrimidinylcarbonyl amino acid piperazide preparation, piperazino carbonylmethylaminocarbonylpyrimidine preparation p2y12 antagonist and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics